Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorCerbaXpert
About this trial
The main objective of the study is to evaluate the frequency of placental transfer of self-Ab directed against the mother's IFN alpha in the newborn, in all women suffering from a pathology frequently associated with the presence of these autoantibodies and in those seropositive during the pregnancy.
Eligibility criteria
Qualifiers
Pregnant woman over 18 years old
Woman whose gestational age is less than 30 weeks.
Having agreed to carry out an assay of anti-IFN alpha IgG auto-Ac before 30 weeks
Give birth in the inclusion center
Disqualifiers
Patient who underwent a blood transfusion less than 2 months ago
Patient who received an organ transplant
Patient undergoing immunotherapy, stem cell therapy and/or other malignancy maternal, under heavy treatment (chemotherapy) less than 6 months before inclusion
Trial design
Treatments tested in this trial
- Pregiferon
Treatment groups
250 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov